Login to Your Account

Deals And M&A NEWS
A consortium of some of China's biggest health care players is snapping up trans-Pacific protein therapeutics developer Ambrx Inc. for an undisclosed amount in a bid to accelerate the introduction of innovative, and presumably more profitable, therapies to the Chinese market.
DUBLIN – Argen-x NV and Leo Pharma A/S entered an alliance, potentially worth more than €104.5 million (US$116 million) on the development of antibody drugs for inflammatory skin conditions, in a move that marks Leo's first foray into biologic drug development.

DUBLIN – Boehringer Ingelheim GmbH is bringing another drug mechanism to bear on NASH, by exercising an option to in-license PXS4728A for €27.5 million up front with about $570 million more to come in milestones.

More Deals And M&A Headlines

Cast Your Vote

Has biotech’s bubble burst?: